[{"orgOrder":0,"company":"Novelty Nobility","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Novelty Nobility \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novelty Nobility \/ Inapplicable"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novelty Nobility \/ GC Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Novelty Nobility \/ GC Biopharma"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Novelty Nobility \/ Novelty Nobility","highestDevelopmentStatusID":"1","companyTruncated":"Novelty Nobility \/ Novelty Nobility"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"ValenzaBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||c-KIT receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novelty Nobility \/ ValenzaBio","highestDevelopmentStatusID":"5","companyTruncated":"Novelty Nobility \/ ValenzaBio"},{"orgOrder":0,"company":"Novelty Nobility","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Novelty Nobility","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novelty Nobility \/ Novelty Nobility","highestDevelopmentStatusID":"4","companyTruncated":"Novelty Nobility \/ Novelty Nobility"}]

Find Clinical Drug Pipeline Developments & Deals by Novelty Nobility

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Novelty Nobility will leverage AGC Biologics’ expertise and proprietary CHEF1® expression technology for cell line development and prepare for Phase I clinical trials

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 05, 2025

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Recipient : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 03, 2025

                          Lead Product(s) : NN3201,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : GC Biopharma and Novelty Nobility established a partnership to jointly research and develop antibody-based protein therapeutics for GA throughout all stages of the drug development lifecycle.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Discovery

                          Sponsor : GC Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Undisclosed,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Recipient : GC Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. ValenzaBio plans to initiate clinical studies of VB517 in 2023.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          February 15, 2022

                          Lead Product(s) : VB517,Inapplicable

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : ValenzaBio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank